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Abstract
Diseases of protein folding arise because of the inability of an altered peptide sequence to properly engage protein
homeostasis components that direct protein folding and function. To identify global principles of misfolding disease
pathology we examined the impact of the local folding environment in alpha-1-antitrypsin deficiency (AATD), Niemann-Pick
type C1 disease (NPC1), Alzheimer’s disease (AD), and cystic fibrosis (CF). Using distinct models, including patient-derived
cell lines and primary epithelium, mouse brain tissue, and Caenorhabditis elegans, we found that chronic expression of
misfolded proteins not only triggers the sustained activation of the heat shock response (HSR) pathway, but that this
sustained activation is maladaptive. In diseased cells, maladaptation alters protein structure–function relationships, impacts
protein folding in the cytosol, and further exacerbates the disease state. We show that down-regulation of this maladaptive
stress response (MSR), through silencing of HSF1, the master regulator of the HSR, restores cellular protein folding and
improves the disease phenotype. We propose that restoration of a more physiological proteostatic environment will
strongly impact the management and progression of loss-of-function and gain-of-toxic-function phenotypes common in
human disease.
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Introduction
The transition from protein folding to misfolding, in both normal
physiology and disease, is dynamically managed by multiple
proteostatic pathways [1,2]. The heat shock response (HSR) is a
central signaling pathway managing the malleable composition of
the proteostasis network (PN) of folding and degradation machin-
eries. The cellular PN environment contributes to what we refer to
as the quinary (Q) state of the protein fold [3–6], which emphasizes
that the structure of a protein is tightly integrated with a dynamic
proteostatic system to direct structure–function relationships in
health and address challenges in response to disease [1,5,7–11]. Q-
state managers of each protein fold draw from the proteostasis pool
of molecular chaperones (Hsp40s, Hsc70s, Hsp70s, and Hsp90),
small heat shock proteins, and ubiquitin-based degradation
components [3,5,12–14]. These managers are responsive to
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multiple signaling pathways including the unfolded protein response
(UPR) [15], controlling compartmentalized folding, and the heat-
shock response (HSR), controlling cytoplasmic/nuclear folding [8].
The importance of an integrated Q-state is exemplified in the
function of coupled protein synthesis and folding machineries [16],
linked cargo-specific folding and trafficking machineries [1,5,7–
9,17], and the activity of cytoplasmic Q-bodies that actively monitor
the health of each protein in the cytoplasm [6,18]. Together, these
proteostasis machineries operate as integrated sensors of individual
protein structure–function relationships that now need to be
understood [3,6,19–24].
The HSR is controlled by the heat shock transcription factor 1
(HSF1), with the chaperone Hsp90 regulating its activation [8,25].
Transient stimulation of the HSR pathway, based on the heat
shock paradigm [26], is generally beneficial in that it alters the
composition of proteostasis components in the cytosol to provide
immediate, but temporary, protection to misfolded proteins in the
face of divergent stress insults [8,9,27]. Consistent with this view,
transcriptional profiling, in response to acute heat shock, revealed
that approximately 500 genes are up-regulated, whereas more
than 1,000 genes are repressed [28–30], conditions that, if
sustained, could negatively impact cell viability. Our understand-
ing of these complex gene expression changes and their impact on
protein structure–function relationships in response to chronic
folding insults remains to be elucidated.
Diseases of protein folding arise due to the inability of an altered
peptide sequence to properly engage the prevailing local
proteostasis components. Gain-of-toxic-function diseases such as
Alzheimer’s (AD) [31] and inherited loss-of-function diseases such
as alpha-1-antitrypsin deficiency (AATD) [32,33], Niemann-Pick
type C1 disease (NPC1), and cystic fibrosis (CF) [34] present a
unique challenge to cells because of the chronic nature of the insult
[34,35]. A current paradigm in disease biology is that stress
pathways are not sufficiently activated to provide the necessary
protection. Therefore, activation of these pathways, such as the
HSR, should improve folding and/or clearance of disease-related
proteins. Indeed, HSF1 activation has been shown to provide
partial correction for some misfolding diseases [36], however, the
in vivo benefits for the chronic activation of HSF1 have not been
investigated. Recently, HSR activation has been shown to
exacerbate the aggregation of mutant huntingtin protein
(htt-Q91) in a cellular model of Huntington’s disease (HD) [37].
Moreover, sustained HSR activation promotes proliferation of
cancer cells [28,38], a pathologic disease state leading to reduced
human lifespan. In cancer cells, HSF1 drives a distinct transcrip-
tional program from the classical HSR, implying a more complex
function than previously anticipated [39]. We have recently
suggested that HSF1 activators that partially promote correction
of CF do so by activation of unknown cellular pathways [40],
which we now need to understand in the context of the prevailing
proteostasis biology to provide new insights into the evolution of
chronic disease management by the cell [1,5].
Herein we have studied four misfolding disorders to address
central principles in managing chronic protein folding stress in
human disease: (1) the deletion of phenylalanine 508 (F508del)
variant of the cystic fibrosis transmembrane conductance regulator
(CFTR) (F508del-CFTR), a multi-membrane–spanning protein
with large cytoplasmic domains, which fails to traffic to the plasma
membrane and is responsible for 90% of CF cases [10,34]; (2) the
Z-variant of alpha-1-antitrypsin (Z-AAT), which accumulates as a
misfolded polymer in the early secretory endoplasmic reticulum
(ER) compartment, leading to liver disease and chronic obstructive
pulmonary disease (COPD)/emphysema because of its failure to
be secreted and delivered to the lung [32,33]; (3) the I1061T
variant of NPC1, key component in lipid and cholesterol
homeostasis in the late endosome/lysosome (LE/L) compartment,
which fails to traffic from the ER to the LE/L in human disease,
resulting in the lysosomal storage disease NPC1; and (4) AD,
which arises from aberrant Alzheimer precursor protein (APP)
processing and trafficking, resulting in accumulation of extracel-
lular Ab amyloid aggregates [31,41].
Although our primary focus is on the correction of CF disease,
we now show that the long-term expression of disease-causing
misfolded proteins results in what we refer to as a maladaptive
stress response (MSR), a state reflecting the sustained activation of
the HSR pathway, which contributes to disease progression by
undermining the normal folding capacity of cells. We provide
evidence that silencing of HSF1 alleviates the MSR and improves
the multiple disease phenotypes, suggesting a general principle that
chronic alteration of the prevailing PN contributes to the
progression of inherited diseases, a step that will now require
active management to mitigate pathophysiology [1,6].
Results
Chronic Proteotoxic Stress in CF Negatively Impacts
Protein Folding
CF is caused by mutations in the multi-membrane–spanning
protein CFTR, a chloride channel responsible for ionic and fluid
homeostasis in the lung [34]. The F508del variant of CFTR is
characterized by misfolding, ER accumulation, and removal by ER-
associated degradation (ERAD) [34]. F508del-CFTR is retained in
the ER in a Hsp70/90-containing chaperone trap, a step that wild-
type (WT)-CFTR and temperature-corrected F508del (30uC) are
able to navigate [42]. We therefore focused our attention on the
HSR pathway that manages cytoplasmic chaperone biology.
To assess the effect of HSR activation on the folding
environment, we first heat shocked bronchial epithelial cells
(CFBE41o-) expressing WT- or F508del-CFTR and monitored
its impact on CFTR protein stability and trafficking. CFTR
stability and trafficking is monitored by Western blot, in which the
Author Summary
The function of all proteins is dependent on achieving the
correct folded state, a process referred to as protein
homeostasis or proteostasis. Cellular proteostasis is main-
tained by diverse signaling pathways, including the heat
shock response (HSR), which protects proteins in the face
of acute stress. However, genetic disorders are a challenge
to cells, since the mutated protein will often fail to fold
properly and function correctly. We have discovered that
the chronic expression of such disease-causing proteins
can trigger the sustained activation of the HSR in a failed
attempt to correct the associated misfolding defect. Such
chronic HSR activation presents an unanticipated chal-
lenge to the cell by initiating a sustained state of stress
management, which leads to a general protein-folding
deficiency. This in turn further exacerbates the disease
phenotype—a condition we have termed maladaptive. We
show that down-regulation of this maladaptive stress
response (MSR) restores cellular protein folding and
improves the disease condition in loss-of-function disor-
ders such as cystic fibrosis, Niemann-Pick disease and
alpha-1-antitrypsin deficiency, as well as gain-of-toxic-
function diseases such as Alzheimer’s disease. MSR
management therefore potentially represents an impor-
tant therapeutic first step in regulating the progression of
human disease associated with chronic protein misfolding.
The Maladaptive Stress Response in Misfolding Diseases
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ER-localized (band-B) and post-ER glycoforms (band-C) exhibit
a differential migration pattern. Whereas WT-CFTR remained
mostly unaffected, more than 90% of F508del-CFTR was
degraded after 60 min of heat shock (HS) (Figure 1A,B). HS
activation was confirmed by increased HSF1 phosphorylation of
Serine-326 (HSF1-P at S326). Since F508del-CFTR is sensitive to
alterations in temperature, we determined whether the destabili-
zation of F508del was caused by HSR activation and not simply
elevated temperature. For this purpose, we overexpressed a
constitutively active variant of HSF1 (DHSF1186–201) [43,44] with
F508del-CFTR in CFBE41o- cells. Overexpression of active
DHSF1186–201, confirmed by elevated levels of HSF1-P and the
stress-inducible Hsp70 (I-Hsp70), also led to destabilization of
F508del-CFTR (Figure 1C). These data support the conclusion
that activation of the HSR pathway results in destabilization of
F508del-CFTR rather than correcting the stability and trafficking
defect associated with this disease variant. We also observed that in
the absence of HS, F508del-expressing cells already exhibited
increased HSF1-P relative to that seen in WT-expressing cells
(Figure 1A, 1D), revealing that the HSR pathway was already
hyperactive in these cells. To confirm this observation, we
compared additional markers of HSF1 activation, including
HSF1 trimerization and expression of I-Hsp70. Cells expressing
F508del-CFTR exhibited a significant increase in total, trimerized,
and phosphorylated HSF1, as well as increased I-Hsp70 levels
relative to WT-expressing cells (Figure 1D–1F). We also observed
a significant increase in mRNA levels of the HSF1-responsive
genes, HspA1A (I-Hsp70), Hsp90a (I-Hsp90), and DNAJB1
(I-Hsp40), relative to that seen in WT-expressing and in isogenic
cells lacking CFTR (CFTR 2/2) (Figure 1G). Additionally,
silencing of F508del-CFTR led to a significant decrease in HSF1
and HSF1-P expression (Figure S1A, S1B), suggesting that the
observed HSR activation is directly related to the expression of this
misfolded CFTR variant. Temperature correction of F508del,
which corrects its associated stability and trafficking defects, also
led to a reduction in HSF1 and HSF1-P to levels seen in WT-
expressing and CFTR2/2 cells (Figure 1E). Altogether, our
results suggest that the HSR activation observed in F508del-
expressing cells at physiological temperature is a direct conse-
quence of the expression of the misfolded F508del-CFTR.
To address whether the observed HSR activation was in
response to the immortalized CFBE41o- cell line phenotype, we
also examined these markers on patient-derived human bronchial
epithelia (hBE) homozygous for WT- or F508del-CFTR. Consis-
tent with the findings observed in cystic fibrosis bronchial
epithelial (CFBE) cells, F508del-expressing hBE cells also showed
elevated HSF1-P and I-Hsp70 protein levels, as well as increased
I-Hsp70 (HspA1A & A6), I-Hsp90, and I-Hsp40 mRNA levels,
relative to that seen in WT-expressing hBEs (Figure 1H–1J). No
differences were observed in mRNA levels of non-classical HSF1-
responsive genes, previously shown to be increased in cancer cells
(CKS2, LY6K, and EIF4A2) (Figure 1J) [28], suggesting activa-
tion of the classical HSF1 pathway. In order to quantify the
magnitude of this HSR activation, we compared the up-regulation
of the I-Hsp40 and I-Hsp70 protein levels seen in F508del-
expressing cells to that seen after HS. We observed a 1.5- and
2-fold increase in I-Hsp40 and I-Hsp70, respectively, in F508del-
expressing CFBE cells relative to that seen in WT-expressing cells,
whereas a 3.5- and 4-fold increase in I-Hsp40 and I-Hsp70,
respectively, was observed after acute HS (Figure 1K). Thus, the
level of HSR activation seen in response to chronic expression of
F508del-CFTR represents approximately 50% of that seen during
acute HS, indicating the presence of a subacute, chronic activation
of the HSR pathway.
The transcriptional changes reported to occur in response to
HSR activation [28–30] are likely to have a global impact on
cellular function. Thus, we monitored the folding of firefly
luciferase (FLuc), a sensor of folding stress in the cytosol [34,45]
that has also been used to monitor both ER and oxidative stress
[46–50]. Here, we used the FLuc reporter not as an absolute
measure of protein folding, but as a sensor for relative cytoplasmic
folding stress when comparing control with diseased cells.
Importantly, F508del-expressing cells exhibited a 50% reduction
in the specific activity of FLuc compared to WT-expressing cells,
which was restored to WT-like levels in response to F508del
silencing (Figure 1L). Since the chronic activation of the HSR,
observed in response to the expression of a misfolded protein,
negatively impacts the folding of other cellular proteins as reported
by FLuc, a state which is likely to impact multiple cellular
function(s) (Figure 1M), we refer to this altered PN environment as
a maladaptive stress response (MSR).
The Hsp90 Co-chaperone p23 is a Key Regulator of the
MSR
Given the increased activation of HSF1 in cells expressing
F508del-CFTR, we next examined the impact of the Hsp90 co-
chaperone, p23, an important regulator of HSF1 activity
[8,51,52]. Since the MSR is a chronic response, we performed
all small interfering RNA (siRNA) interventions for a total of six
days to allow for appropriate rebalancing of the PN environment.
P23 silencing significantly reduced HSF1 activation in response to
HS, as exemplified by a reduction in the level of HSF1-P
(Figure 2A), confirming its central role in the activation cycle of
HSF1. At physiological temperature, p23 silencing in F508del-
expressing CFBEs also resulted in a significant decrease in HSF1
and HSF1-P protein levels, as well as I-Hsp70 mRNA and protein
levels (Figure 2B, 2C), to a level similar to that seen in WT-
expressing cells (Figure 2D). Furthermore, abrogation of the MSR
following p23 silencing led to a concomitant restoration of FLuc
folding in F508del-expressing CFBEs (Figure 2E).
Silencing of p23 had no effect on HSF1 mRNA level (Figure
S2A) nor on HSF1 stability, determined by pulse-chase (Figure
S2B, S2C). However, we did observe a reduction in the amount of
labeled HSF1 in the pulse-phase (Figure S2B, S2D), indicating a
reduction in HSF1 translation in response to p23 silencing. In
contrast, p23 silencing had no impact on HSF1 levels in WT-
CFTR expressing cells, in which no MSR is detected (Figure S2E),
suggesting that p23 plays a critical role in modulating the MSR
induced in F508del-CFTR expressing cells.
Modulation of the MSR by sip23 Improves F508del
Channel Activity
Since p23 silencing reduced the MSR state in F508del-
expressing cells, we assessed its effect on F508del-CFTR biogen-
esis. P23 silencing resulted in a significant increase in F508del ER
stability (band-B) and trafficking (band-C) compared to control
siRNA treatment (Figure 3A). It also resulted in an increase in the
trafficking index, defined as the ratio of band-C to band-B (C/B)
[53], an indicator of its post-ER stability (Figure 3A). These results
suggest that a reduction of the MSR, which restores a WT-like PN
state (Figure 2D), supports the increased trafficking efficiency of
F508del similar to what is observed following 30uC correction
(Figure 3B), providing significant benefit to the CF phenotype.
P23 silencing did not increase WT stabilization or trafficking
(Figure 3C), indicating that its effect on F508del correction occurs
in response to alleviation of the MSR exclusively seen in F508del-
expressing cells.
The Maladaptive Stress Response in Misfolding Diseases
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Figure 1. Expression of F508del induces chronic proteotoxic stress that affects cellular protein folding. (A) Immunoblots of WT-CFTR,
F508del-CFTR, and HSF1-P during HS time course (42uC for a total of 60 min). (B) Quantification of total CFTR during HS, relative to pre-HS (T = 0)
(n=4). (C) Immunoblots of indicated proteins in CFBE41o- cellular lysates following the co-expression of F508del-CFTR with the constitutively active
DHSF1186–201 or control empty plasmid. (D) Immunoblots of HSF1-P and I-Hsp70 in WT or F508del expressing cells (n= 4). (E) Quantification of the
expression of HSR markers in WT-CFTR, F508del-CFTR at 37uC or 30uC, and CFTR null (CFTR2/2) expressing cells. (F) Quantification of HFS-1 trimer
The Maladaptive Stress Response in Misfolding Diseases
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CFTR pulse labeling in response to sip23 revealed a significant
increase in the synthesis of F508del-CFTR but not of WT-CFTR
(Figure S3B, S3D), consistent with the results presented above for
the steady-state levels of CFTR (Figure 3A, 3C). This differential
synthesis could be due to change in transcription, translation and/
or post-translational stability of F508del-CFTR. Although p23
levels in WT-, F508del- and CFTR null–CFBE cells. (E,F) Results are shown as percentage of that seen in WT-expressing cells, as a mean 6 standard
error of the mean (SEM), n$3. qRT-PCR of I-Hsp70 (HspA1A, or HspA6), I-Hsp90 (Hsp90a), and I-Hsp40 (DNAJB1) in (G,J) or of cancer-related HSF1
responsive genes (CKS2, LY6K, EIF4A2) shown in (J) from mRNA isolated from WT-, F508del- and CFTR null–CFBE cells (G) or from mRNA obtained
from hBE primary cells obtained from homozygous patients for WT- or F508del-CFTR (J). qRT-PCR data was normalized to the housekeeping gene
beta-glucuronidase (GUS). Results are shown as percentage of WT-expressing cells set to a 100 (mean 6 standard deviation [SD] or SEM, n$3, and *
indicates p,0.05 relative to WT). Immunoblot (H) and quantification (I) of CFTR, HSF1-P, and I-Hsp70 from hBE primary cell lysates of WT or F508del
patients. Data is shown as the relative protein expression normalized to actin (mean 6 SD, n$2). (K) Quantification of I-Hsp70 and I-Hsp40 protein
level in F508del-expressing cells at 37uC (MSR) or following acute HS (shown as a percentage of the level seen in WT-expressing cells; mean6 SD, n$
2). (L) Firefly luciferase (FLuc) activity in WT- and F508del-CFTR expressing cells following siCFTR silencing. Results represent normalized specific
activity of FLuc (luminescence/relative FLuc expression) for each condition. Data is shown as percentage of WT-CFTR expressing cells, mean 6 SEM,
n$3, and *, # indicate p,0.05 relative to WT and F508del (0 nM siCFTR), respectively. (M) (1) Diagram showing the proteostatic environment of WT
folding, where substrates are properly managed by the physiological Q-state (yellow cloud). (2) Representation of the transient stress level observed
during acute stress responses (dotted red line). (3) The MSR state induced in misfolding diseases (abnormal Q-state, gray cloud) that results in a
continuous elevated (subacute) stress affecting global folding and cellular function. All experimental data was repeated at least once. The underlying
data used to make (B), (E–G), and (I–L) in this figure can be found in the supplementary file Data S1.
doi:10.1371/journal.pbio.1001998.g001
Figure 2. p23 Hsp90 co-chaperone is a modulator of the MSR. (A) Quantification of HSF1-P after 1 h HS in F508del-expressing cells treated
with control or p23 siRNA. Data is shown as percentage of control (mean 6 SEM, n = 4). (B) Immunoblot of the indicated proteins following p23
silencing in F508del-CFTR expressing cells. Histograms represent quantification of the indicated proteins upon sip23, relative to levels seen with
control siRNA, which is set to 100%. (C) qRT-PCR analysis of I-Hsp70 in F508del-expressing cells following sip23. The data represent a ratio of I-Hsp70
to the housekeeping gene (GUS) and are shown as percentage of control siRNA. All results are shown (B,C) as a mean6 SEM, n$3, and * indicates p,
0.05 relative to control. (D) Quantification of HSF-1-P and I-Hsp70 protein levels in WT- and F508del- expressing cells after control or sip23 treatment.
The data is shown as a percentage of F508del-expressing cells, and # represents p,0.05 relative to F508del (mean 6 SEM, n$3). (E) Quantitative
analysis of FLuc activity in WT- and F508del-CFTR expressing cells treated with control or sip23. The data represents normalized specific activity of
FLuc (luminescence/relative FLuc expression) for each condition (mean 6 SEM, n$3). All results were replicated at least once. The symbols * and #
represent p,0.05 relative to WT and F508del respectively. The underlying data used to make (A–E) in this figure can be found in the supplementary
file Data S1.
doi:10.1371/journal.pbio.1001998.g002
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down-regulates the transcription of the glucocorticoid and thyroid
hormone receptors [54,55], we did not observe any changes in
WT- or F508del-CFTR mRNA levels (Figure 3D). However, p23
silencing did significantly reduce the degradation rate of F508del-
CFTR but not that of WT-CFTR (Figure S3A, S3C), suggesting
that p23 specifically affects the stability of nascent F508del-CFTR.
Increased F508del stability was not due to altered proteasome
activity, since combining sip23 with the proteasome inhibitor,
MG132, resulted in an additive effect on F508del stability and
trafficking (Figure S3E). In support of this conclusion, the levels of
ubiquitinated F508del following sip23 also remained unchanged
(Figure S3F). p23 silencing also promoted a significant reduction of
Hsc/p70 and Hsp90 (Hsp90a and Hsp90b) levels recovered in
F508del-CFTR immunoprecipitates (Figure 3F), indicating that
Figure 3. Silencing of p23 improves F508del-CFTR function in CF by down-regulation of the MSR. Immunoblot of CFTR following sip23
treatment of F508del-expressing cells at 37uC (A) and 30uC (B) or WT-expressing cells (C). Histograms show quantification of CFTR band-B and C
glycoforms and C/B ratios. Results are shown as a percent of the maximal signal for band-B glycoform and as fold change relative to control (set to 1)
for the ratio C/B (mean 6 SEM, n$3). (D) qRT-PCR analysis of CFTR and p23 levels following p23 silencing in WT or F508del-expressing cells. Results
represent a ratio of the indicated mRNA to GUS, and shown as the percent of siRNA control (mean 6 SEM, n$3). (E) Iodide efflux analysis of F508del-
expressing cells in response to p23 siRNA or 30uC correction. Results are shown as a ratio of the efflux at stimulation (stim) to efflux at pre-stimulation
(basal) (mean 6 SD, n$3). (F) Immunoblot of the indicated proteins in the cell lysate (input) or following CFTR IP (right panels) in response to sip23
treatment (CFTR2/2 cells were used as a negative control for the CFTR IP). Histogram shows quantification of recovered Hsc/p90 (a and b) and Hsc/
p70 by co-IP with CFTR. The data is shown as a ratio of the recovered chaperone to total CFTR and normalized to 1 for the control siRNA (mean6 SD,
n = 3, replicated three times). For all data, * indicates p,0.05 relative to control, and results were replicated at least once. The underlying data used to
make (A–F) in this figure can be found in the supplementary file Data S1.
doi:10.1371/journal.pbio.1001998.g003
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abrogation of the MSR allows F508del-CFTR to properly
navigate early folding intermediates known to contribute to the
ER retention of F508del-CFTR [42].
Given the observed correction of the F508del-CFTR trafficking
defect by p23 silencing, we assessed whether the corrected pool of
F508del was functional. F508del-expressing cells treated with
sip23 exhibited a significant increase in channel activity, as
determined by iodide efflux (Figure 3E) and short circuit current
(Isc) recordings (see below, Figure 4B). Our results show that
abrogation of the MSR by p23 silencing promotes trafficking of a
functional F508del-CFTR to the cell surface.
MSR Poses a General Challenge to Misfolding Diseases
Since the expression of F508del-CFTR results in chronic
activation of HSF1, which not only affects F508del biogenesis
but also the activity/folding of other cellular proteins (Figure 1L),
we tested whether HSF1 silencing would also correct the
trafficking defect associated with F508del-CFTR. HSF1 silencing
resulted in a significant increase in ER stability (band-B),
maturation (band-C) and trafficking index for F508del-CFTR
(Figure 4A and Figure S4A). Furthermore, it also led to increase in
F508del function by Isc recordings to the level seen with siHDAC7,
a validated siRNA target for correction of CF [56], and with
VX809, a CF corrector currently in clinical trials for the treatment
of F508del homozygous patients (Figure 4B) [57,58].
In order to determine whether the MSR observed in CF is a
general phenomenon associated with protein misfolding diseases,
we monitored the HSR activation state in models of AATD,
NPC1, and AD. In AATD, the G342K mutation in AAT, referred
to as the Z-variant, results in ER-retention, polymerization, and
degradation of this normally secreted enzyme, the loss of which
leads to COPD [32,59]. Cells expressing the Z-variant exhibited
higher levels of HSF1-P compared to WT-AAT expressing cells
(Figure 4C and Figure S4B), suggesting, once again, the existence
of a MSR. Furthermore, HSF1 silencing resulted in increased
maturation (AAT-M) and secretion (AAT-S) of the mutant Z-AAT
(Figure 4D and Figure S4C, S4E); however, no changes in the
polymerization state of the Z-AAT variant were observed
(Figure S4D). This result is consistent with the effect of other
correctors, such as suberoylanilide hydroxamic acid (SAHA), in
which increased maturation and secretion of Z-AAT is observed
without changes in polymerization [33]. Thus, MSR abrogation
also provides benefit to a protein misfolding disease found in the
ER lumen [9,33], suggesting a link between ER stress biology [15]
and cytoplasmic stress management by HSR. This observation is
consistent with previous results suggesting a crosstalk between
these pathways [60]. In addition, genomic analysis has revealed
that transcriptional targets of HSF1 found in the secretory
pathway are also induced by UPR [61–63], providing a
mechanism by which silencing of HSF1 could be beneficial for
AATD.
We next investigated whether a MSR arose in response to the
I1061T variant of the NPC1 protein responsible for the lysosomal
storage disease Niemann-Pick type C1, which, like CF, is
characterized by protein misfolding and ERAD-mediated clear-
ance [64]. An analysis of human primary fibroblasts from
homozygous I1061T NPC1 patients and healthy donors (WT)
reveals that cells expressing the I1061T variant exhibit an
elevation in the levels of HSF1-P, suggesting the presence of a
MSR (Figure 4E and Figure S4F). Here HSF1 silencing also
improved the trafficking defect of I1061T-NPC1, as exemplified
by the increased endo H resistance reflecting modification of its
N-linked oligosaccharides by Golgi enzymes, relative to that seen
with control siRNA (Figure 4F).
We then examined a Caenorhabditis elegans model of cytoplas-
mic amyloid aggregation. C. elegans expressing the b-amyloid-42
(Ab42) peptide fused to CFP (Ab42-CFP) under the control of a
muscle-specific unc-54 promoter forms CFP-positive Ab aggre-
gates in the cytoplasm of muscle cells (Figure S5A, S5B). The
C. elegans model has been extensively used in the field of
misfolding diseases and is a validated tool to study the impact of
amyloid disease in organismal models [19,21,65,66]. Here we
observed an increase in I-Hsp70 level in Ab42 worms (,150-fold,
Figure S5C), which was not further up-regulated after HS as seen
in WT worms. Up-regulation of I-Hsp70 was reduced in response
to HSF1 silencing or reduction of Ab42 expression (Figure S5D),
indicating that the misfolding stress caused by Ab42 expression also
induces a MSR state. Accumulation of cytosolic Ab42 aggregates
led to paralysis in 75% of diseased worms relative to its WT
counterparts, which was significantly reduced by silencing of not
only Ab42 (silencing of yellow fluorescent protein- [siYFP]) but also
in response to I-Hsp70 and HSF1 silencing (Figure S5E, S5F).
Conversely, HSF1 overexpression resulted in increased Ab42
induced proteotoxicity with an approximately 30% increase in
paralyzed worms (Figure S5G).
To extend these observations to a neurodegenerative model of
Ab42 amyloid aggregation, we examined the expression levels of
HSF1 and HSF1-P (phosphorylated at T142) [67] in brain
homogenates of WT and AD mice (AbPP Tg) at three different
ages (approximately 4 mo, 9 mo, and 16 mo old). We observed a
significant increase in both HSF1 and HSF1-P expression in all
AD mice compared to their age-matched WT counterparts
(Figure 4G). The toxic Ab42 amyloid species (4 kDa monomer
and 6-12 kDa multimers) [68,69], previously characterized in this
Figure 4. HSF1 silencing increases F508del folding, trafficking, and function and improves the phenotype of other misfolding
diseases. (A) Immunoblot of indicated proteins following siHSF-1. (B) Short-circuit current (Isc) analysis of CFTR in polarized CFBE cells expressing WT-
or F508del-CFTR treated with the indicated siRNA or temperature corrected at 30uC. Channel activity was determined in response to forskolin and
genistein (positive deflection) or with CF specific inhibitor 172 (Inh172) (negative deflection). The ** indicates p,0.05 and * indicates p,0.1 relative
to control siRNA or DMSO for VX809 (n$4). (C) Immunoblot of the indicated proteins in WT- and Z-AAT expressing IB3 cells (n= 3). (D) Immunoblot of
the indicated proteins in Z-AAT expressing IB3 cells in response to siHSF1 treatment. Shown for the AAT are the immature (I), mature (M), and
secreted (S) forms (n= 3). (E) Immunoblot of the indicated proteins from primary fibroblasts derived from WT- or mutant I1061T-NPC1 patients (n= 3).
(F) Immunoblot of the digestion pattern before and after endo-H digestion of WT- or mutant I1061T-NPC1 stably expressed in Hela cells and treated
with the indicated siRNA (n= 3). Immunoblot shows NPC1 endo-H resistant band (R) and sensitive band (S). Quantification represents total I1061T
NPC1 (R+S) in control or siHSF1-treated cells, shown as percentage of control. Percentage of endo-H sensitive band (S) or resistant band (R) is shown
in gray and black color, respectively (n$3, * indicates p,0.05). (G) Immunoblots of indicated proteins and quantification of HSF1 and HSF1-P on brain
homogenates obtained from WT or AD mice of approximately 4 months (4 m; n= 3 for WT, n= 3 for AD), 9 months (9 m; n= 2 for WT, n= 2 for AD),
and 16 months of age (16 m; n=3 for WT, n= 3 for AD). Results were normalized to tubulin loading control and shown as fold change relative to WT-
3m set to 1 (* indicates p,0.05 relative to age-matched WT mice). (H) Immunoblot for APP (110 kDa), Ab42 toxic species (monomer, 4 kDa, and
multimers from 6–12 kDa), and actin control on particulate fractions of brain homogenates obtained from WT (on the right) or AD mice. Controls
shown include 0.5 mg recombinant Ab42; control and Alzheimer disease samples from human brain homogenates. The underlying data used to make
(B), (F) and (G) in this figure can be found in the supplementary file Data S1.
doi:10.1371/journal.pbio.1001998.g004
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AbPP Tg mice model [70], were detected in brain homogenates
from AD mice but not in that of WT mice. The accumulation of
Ab42 amyloid in AD mice was also age dependent (Figure 4H),
consistent with previously published studies showing age-
dependent increase in Ab plaques, and mean plaque size on these
mice [70]. Despite the age-related increase in toxic amyloid, we
did not observe an age-dependent increase in HSF1-P in the AD
mice, a result consistent with the known decline of proteostatic
capacity as has been previously documented in aging organisms in
the face of increasing cellular stress [71–73].
Silencing of HSF1 Improves F508del Folding and Its Cell
Surface Stability
The MSR is a chronic state transferring the misfolding
challenges to all aspects of cellular folding biology managed by
proteostasis components impacting the activity of the Q-state of
F508del [42]. Thus, we examined in more detail the impact of
HSF1 silencing, which in our CF cell model resulted in increased
stability and trafficking of F508del-CFTR at steady state
(Figure 4A). To address whether the observed increased in
F508del stability reflected an increase in global protein synthesis,
we compared the level of S35-labeled proteins in cellular lysates
from F508del-expressing cells in the presence or absence of
siHSF1 to that seen in WT-expressing cells. Strikingly, we first
observed that MSR-affected F508del-expressing cells exhibited a
drastic decrease in total protein synthesis, representing less than
50% of that seen in healthy WT-expressing cells (Figure 5A). This
highlights the negative impact of MSR activation on the proteome
and is consistent with attenuation of protein synthesis seen in
numerous types of stress [74]. HSF1 silencing had no impact on
the level of total protein synthesized in F508del-expressing cells
(Figure 5A); however, we did observe an increase in F508del
synthesis after pulse labeling, followed by increased stability of de
novo synthesized F508del band-B in the chase phase of the
experiment (Figure 5B). We also observed increased stability of
band-C after inhibition of de novo protein synthesis by cyclohex-
imide (CHX) treatment (Figure 5C). To determine if band-C
stability resulted from increased band B to C trafficking following
CHX treatment, we used brefeldin A (BFA) to block ER to the
Golgi trafficking and track the stability of rescued F508del-CFTR
(rF508del) band-C by preventing egress to the cell surface. The
half-life (T1/2) of band-C in temperature-rescued F508del
(rF508del) was approximately 2 h, whereas HSF1 silencing
significantly increased the stability of the rF508del pool, exhibiting
a T1/2 of 6 h, a value similar to that seen for WT-CFTR
(Figure 5D). These data suggest that alteration of the MSR by
siHSF1 increases the stability of rF508del band-C, possibly as a
result of improved protein folding.
To directly address whether we have achieved improved protein
folding following siHSF1, we used limited trypsin proteolysis, a
method previously shown to distinguish between the stable and
destabilized fold of the WT and F508del variants, respectively
[75]. We used antibodies specific for the first nucleotide binding
domain (NBD1: 18D1) and second nucleotide binding domain
(NBD2: M3A7) of CFTR, to assess the susceptibility of these
domains to resist proteolysis. HSF1 silencing leads to a significant
stabilization of both NBD1 and NBD2, exhibiting a more
pronounced stabilizing effect to that seen with temperature
correction (Figure 5E). It also led to the appearance of an
approximately 25 kDa band in NBD1, which has previously been
described to represent the stable core fragment seen in WT-
CFTR, but not in the F508del variant [75]. HSF1 silencing also
restored the folding of the FLuc reporter to a level comparable to
that seen in sip23-treated F508del-expressing cells and WT-
expressing cells (Figure 5F). Overall our results suggest that
alleviation of the MSR by siHSF1 generates a more permissive
cellular environment for productive folding, not only improving
the CF phenotype but also that of other protein misfolding diseases
by restoring a WT-like proteostasis environment.
To understand the impact of HSF1 silencing on F508del-CFTR
stability, we performed gene expression analysis. Here we found
that HSF1 or p23 silencing leads to a reduction in the expression
of HSF1-responsive genes, such as I-Hsp70, HSPB1, and I-Hsp40.
However, they had no effect on the transcription of CFTR itself
(Figure S6A), nor the expression levels of markers for other PN
cellular pathways, including ubiquitin proteasomal system (UPS),
autophagy, and oxidative stress (NRF2 pathway) (Figure S6B). In
addition to the alleviation of the HSR, both siHSF1 and sip23 also
decreased the expression of UPR-related genes (Figure S6B). UPR
but not the oxidative stress pathway was up-regulated in F508del-
expressing cells in comparison with WT-expressing or CFTR2/2
cells (Figure S6C), suggesting a link between HSR and UPR
activation, as previously described [60].
Finally, we used the proteasomal inhibitor MG132 and the
autophagy inhibitor 3-methyladenine (3-MA) to examine the
impact of proteasome and autophagic pathways on the FLuc
folding sensor. Whereas HS of F508del-expressing cells further
reduced FLuc activity and folding from a level of 50% to 25% of
that of WT-cells (Figure S6D), neither MG132 nor 3-MA impacted
FLuc folding in F508del-expressing cells. These results suggest that
blocking proteasomal activity or autophagy is not sufficient to rescue
FLuc folding in an environment already affected by the MSR.
Figure 5. Silencing of HSF1 improves F508del folding and its cell surface stability. (A) Total protein synthesis on S35 labeled samples from
WT- or F508del-CFTR expressing cells treated with control or siHSF1. Results are shown as percent of WT for total protein normalized by number of
cells in each condition (mean 6 SEM, n=3; * indicates p,0.05 relative to WT). (B) Pulse-chase of F508del-CFTR in response to siHSF1 treatment.
Numbers show percent of F508del relative to time 0 (T = 0; n=2). (C) F508del-CFTR immunoblots and quantification in control or siHSF1 transfected
cells before (T = 0) and after cycloheximide (CHX; 50 mM) chase for the indicated time (h). Results are shown as percent of band-B or band-C at T = 0
(mean 6 SD, n$4). (D) CFTR immunoblots and quantification in WT or F508del corrected at 30uC or by siHSF1 before (T = 0) and after brefeldin A
treatment (BFA; 5 mg/ml) for the indicated time (h). The data is presented as a fraction of maximal band-C set to 1 at 1 h post-BFA treatment and
represents the mean 6 SD, n$4. (E) Representative immunoblots from three experimental replicates of CFTR—WT, F508del at 37uC, F508del at 30uC,
or F508del siHSF1—before and after proteolysis digestion with increasing concentration of trypsin (mg/ml). Upper blots show digestion pattern of
CFTR NBD1 domain (18D1 antibody), and lower blots show digestion pattern of CFTR NBD2 domain (M3A7 antibody) (* indicates stable core
fragment previously described) [75]. (F) Quantification of FLuc activity in WT- and F508del-CFTR expressing cells treated with the indicated siRNA. The
data represents specific FLuc activity (luminescence/relative FLuc expression) for each condition. Results are shown as a mean 6 SEM, n$3; * and #
indicate p,0.05 relative to WT- and F508del-CFTR, respectively. The underlying data used to make (A), (C), (D) and (F) in this figure can be found in
the supplementary file Data S1.
doi:10.1371/journal.pbio.1001998.g005
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Chemical Inhibition of HSF1 Activation Promotes
Correction of CF
Given the impact of the MSR on the recovery of F508del
function, we tested the effect of chemical inhibition of HSF1 in
F508del-expressing CFBEs, using the previously characterized
HSF1 inhibitor, triptolide [76]. Triptolide reduced the HS-
induced up-regulation of I-Hsp70 and I-Hsp90 mRNA levels
(Figure S7A), confirming its ability to block HSF1 transactivation,
consistent with previously published data [76]. Treatment of
F508del-expressing cells with triptolide resulted in an increase in
band-B stability as well as trafficking to band-C (Figure 6A). It also
restored cell surface channel activity shown by quenching of the
halide sensing YFP-H148Q/I152L (Figure 6B), to a level similar
to that seen with VX809 (Figure 6B). Since misfolding diseases
present a chronic challenge to the cell, we next assessed the benefit
a chronic dosing regimen of triptolide on correcting the F508del-
CFTR trafficking defect. Chronic treatment resulted in a time-
dependent increase in stabilization and trafficking of F508del-
CFTR over the course of 96 h (Figure 6C). The effect of
triptolide was dependent on HSF1, since combining triptolide
and siHSF1 did not result in additivity for F508del stability,
trafficking, and function (Figure S7B), further supporting the
conclusion that suppression of HSF1 hyper-activation promotes
F508del correction.
Since down-regulation of the MSR provides a favorable
environment for protein folding and trafficking of F508del-CFTR,
we re-assessed the potency of existing correctors of F508del-CFTR
in combination with triptolide or siHSF1. Treatment of F508del-
expressing cells with VX809 or triptolide alone led to a moderate
restoration of F508del-CFTR activity (Figure 6B). In contrast,
combining both drugs had a synergistic effect on F508del-CFTR
trafficking and channel activity (Figure 6D, 6E and Figure S7C).
Similar results were also observed with siHSF1 in combination
with VX809 and other CF correctors (Figure S7D), showing that
alleviation of the chronic stress improves the potency of clinically
relevant correctors of F508del trafficking and function.
Abrogation of the MSR Increases F508del Function in CF
Patient-Derived Bronchial Epithelia and Intestinal
Organoids
We next examined the effect of triptolide treatment in
patient-derived bronchial hBE cells homozygous for F508del.
Treatment with triptolide resulted in a modest 1.4-fold increase
in short-circuit current (Isc) relative to that seen with vehicle
treatment (Figure 7A). Maximal correction was obtained
when triptolide was combined with VX809, resulting in a
7-fold increase in Isc over the basal current (Figure 7A, 7B),
synergizing with the VX809 effect, which achieved a 3.5-fold
increase in Isc. To address whether this effect was tissue specific,
we also tested the effect of triptolide using primary CF intestinal
organoids derived from two F508del CF patients [77]. In this
assay, increased organoid swelling is indicative of restored
F508del function. Although we did not observe any effect with
triptolide alone, we did observe an approximate 50% increase in
organoid swelling when VX809 was combined with triptolide as
compared to that seen with VX809 alone, revealing a synergistic
response in both CF patient codes (Figure 7C, 7D), similar to
that seen in primary hBE and CFBE cells. These results
highlight the beneficial impact of MSR abrogation and its
ability to improve the potency of existing therapeutics,
consistent with our hypothesis that restoration of a WT-like
folding environment could be a critical factor in managing
human misfolding disease [5,9].
Discussion
Our results demonstrate that the long-term expression of
disease-causing misfolded proteins can lead to an abnormal,
chronic stress response that we now refer to as the maladaptive
stress response (MSR). This altered Q-state [3–6], which
emphasizes that the structure of a protein is tightly integrated
with a dynamic proteostatic system [1,5,6,9], negatively impacts
the folding of disease-associated proteins, such as F508del-CFTR
[42], leading to a self-propagating proteotoxic crisis (Figure 8). We
have found that targeting the MSR can significantly alleviate
disease progression, thereby improving the disease phenotype in
different disease models of protein folding. In CF, this is consistent
with the view that folding of CFTR is a multi-step, vectorial
process involving sequential folding intermediates that must be
therapeutically managed for effective correction [42,78,79]. We
now suggest that restoration of the native cellular proteostasis-state
could represent a critical first line of therapeutic intervention to
more effectively achieve the correct structure–function relationship
necessary to restore cellular function.
Our results show that the proteostatic biology of F508del-
expressing cells is different than that seen in WT-expressing cells,
characterized by a subacute increase in heat shock protein
expression, reduced protein synthesis, and altered protein folding,
phenomena contributing to the disease phenotype that we have
referred to in the past as the chaperone trap [42]. These results are
consistent with previous observations where elevated levels of heat
shock proteins were observed in postmortem brain tissue of AD
patients [80–83], and in lung tissue of COPD patients [84]. Our
proposed paradigm shift in how to address protein misfolding
diseases leads us to suggest that, unlike the well-documented
protective benefit of HSR activation to solve acute and transient
protein misfolding problems (see below) [40], the MSR is
counterproductive when chronically activated, attempting to
repeatedly manage a misfolding problem that it cannot solve.
This condition thereby exacerbates the disease rather than
relieving it, emphasizing the importance of first managing the
disease from the perspective of proteostasis by mitigating the
chronic folding stress problem. We propose that abrogation of the
MSR, either by directly stabilizing the initiating misfolding
intermediate [34,85,86] or, as suggested herein, through restora-
tion of a WT-like Q-state [5,6,9], could provide substantial benefit
to counter the proteotoxic crisis found in chronic disease
(Figure 8).
It is becoming increasingly evident that there exists a fine
balance between protection and toxicity in the function of the
protein folding environment in eukaryotic cells [2,5,6,22,87]. On
one hand, the beneficial impact of HSR activation in preventing
proteotoxicity in worm and mouse models of HD and AD [88–90]
and in promoting cell survival in the face of diverse stress insults
has been well documented [8,9,27]. Additionally, HSF1 activators
and overexpression of select chaperones have been shown to be
neuroprotective [36,91–93]. However, the mechanism of action of
such compounds and the chronic effect of HSF1 activation in vivo
remain to be elucidated. Proteostasis regulators shown to activate
HSF1 and to provide benefit in HD have also been shown to affect
other stress pathways, including oxidative stress and UPR, which
could contribute to disease management [36]. HSF1 overexpres-
sion has also been shown to exacerbate mutant Htt aggregation in
a cellular model of HD [37]. On the other hand, Hsps are known
to be actively involved in disease progression [80,82,83]. For
example, in tau pathology, Hsp90 binding promotes tau misfold-
ing and aggregation [94], not unlike the chaperone trap state
found in CF [42,78,79], a result consistent with the dynamic state
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of the disordered tau protein and its interaction with Hsp90 in
disease [95]. Moreover, chaperone balance is disrupted upon
overexpression of polyQ aggregates through sequestration of low-
level expression regulatory co-chaperones required for protein
folding [96]. While Hsp90 inhibitors, which indirectly activate
HSF1, show promise in treating neurodegenerative diseases
[97,98], the beneficial effect was shown to be directly due to
Hsp90 inhibition, which, in the case of tauopathies, reduces the
functional cycling of kinases and thereby tau phosphorylation,
minimizing its aggregation and toxicity [99,100]. Thus, while the
mechanism of action of HSF1 activation is poorly understood,
perhaps reflecting experimental conditions where a ‘brief’ burst of
chaperones provides temporary relief to the misfolding problem,
there is limited evidence in vivo that chronic activation of HSF1
provides long-term disease benefit. Indeed, proliferation of cancer
cells is also dependent on a MSR characterized by sustained HSR
Figure 6. Chemical inhibition of HSF1 improves F508del-CFTR function. Immunoblot and quantification of CFTR following treatment of
F508del-CFTR–expressing CFBE cells with increasing concentration of triptolide (Trip.) alone (A) or in combination with the CF corrector VX809 (D).
Results are expressed as percentage of maximum signal of CFTR band-B (set at 100%), and shown as mean6 SEM, n$3; * represents p,0.05 relative
to DMSO. (C) Immunoblot and quantitative analysis of CFTR following a daily chronic dosing regimen (96 h) of 12 nM triptolide in F508del-CFTR
expressing cells. Results are expressed as fold change relative to DMSO, and shown as mean 6 SD, n= 2; * represents p,0.05 relative to DMSO. YFP-
quenching curves of F508del-CFTR expressing CFBE-YFP cells treated with the indicated compounds for 24 h alone (B) or in combination (E) (mean6
SD, n$3). All results were repeated at least once. The underlying data used to make (A–E) in this figure can be found in the supplementary file
Data S1.
doi:10.1371/journal.pbio.1001998.g006
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Figure 7. Chemical inhibition of HSF1 synergizes with VX809 to improve F508del-CFTR function in patient-derived primary
epithelium. (A) Short-circuit current analysis of human primary hBE cells (F508del/F508del, patient code CF006) treated with DMSO, 3 mM VX809,
and 25 nM triptolide or a combination of VX809 and triptolide, for 96 h (daily dosing). The data is presented as fold change relative to the basal
current seen with DMSO treatment, and shown as mean 6 SD, n$3 (replicated multiple times); * and # indicate p,0.05 relative to DMSO or VX809,
respectively. (B) Representative short-circuit current (Isc) traces for DMSO, VX809, triptolide, or triptolide + VX809 treatment of primary hBE cells from
(A). (C) Quantitative analysis of organoid swelling (shown in D) that is indicative of CFTR function over the period of 60 min. Organoids were obtained
from two distinct F508del/F508del CF patients (CF4, CF22), and treated with DMSO, 3 mM VX809, 25 nM triptolide, or a combination of VX809 and
triptolide. Experiments were repeated once and results are shown as a mean 6 SD, n$2; * and # indicate p,0.05 relative to DMSO or VX809,
respectively. (D) Representative images of organoids derived from patients (CF4 and CF22) at T = 0 or after stimulus with Forskolin/Genistein at
T = 60 min treated with the indicated compounds. Scale bar represents 110 mm. The underlying data used to make (A–C) in this figure can be found
in the supplementary file Data S1.
doi:10.1371/journal.pbio.1001998.g007
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activation and elevated levels of proteostatic components that
sustain invasive survival [28,38], a pathological condition leading
to reduced human lifespan.
The global proteotoxic crises that arise in protein misfolding
diseases may be a consequence of an amplifying cascade of
misfolding challenges as disease progresses, a view consistent with
reports of reduced longevity in worms following chronic overex-
pression of misfolded proteins [35,90,101,102]. Alternatively,
disease progression could reflect either the loss of proteostatic
capacity associated with aging [4,8,21,73,103–105] or an overload
of the cellular PN capacity. In the latter case, since Hsc/Hsp70
and Hsp90 represent at least 0.5% and 1% of total cellular protein,
respectively, and cells exhibiting a MSR have reduced global
protein synthesis, it is unlikely that the chaperone capacity per se is
saturated, but this remains to be tested directly, given the
complexity of the folding environment and lack of understanding
of chaperone capacity in each cell type and/or disease environ-
ment. However, we have observed that the silencing of key
proteostatic chaperones leads to a partial rescue of F508del-CFTR
cell surface channel activity (Figure S7E) [106], arguing against a
possible overload of the chaperone capacity, at least in CF disease.
Indeed, the reduced specific activity of the FLuc sensor suggests a
significant challenge to the overall cellular folding environment, a
result that is consistent with the recent observation that
overexpression of the Hsp40/70 system decreases the fraction of
protein that achieves a functional fold using activity-based
profiling [11]. These observations underline the importance in
understanding folding mis-management by the chronic MSR that
exceeds a set-point defined by chaperone/co-chaperone balance
normally required for a healthy cell. It is clear that this new
principle of short-term acute versus long-term chronic proteostatic
set-points now needs to be considered as an important contributor
to the onset and progression of misfolding diseases such as CF,
AATD, NPC1, and AD. For example, the activity of FLuc, a
sensor of the folding environment of the prevailing PN [45,46–50],
in cells chronically expressing the misfolded F508del-CFTR was
reduced in response to elevated HSF1 activity, but restored to
WT-levels upon MSR abrogation by siHSF1, sip23 or, impor-
tantly, following removal of the misfolded F508del-CFTR. Here,
we suggest that p23, acting in concert with Hsp90 in protein
folding and transcriptional activation of HSF1, accentuates the
activity of the chaperone trap components, engaging F508del in
an inappropriate attempt to resolve progression along the folding
pathway [42]. Consistent with this conclusion, we observed HSF1
phosphorylation and I-Hsp70 levels, in response to sip23, reduced
to the levels seen in WT-expressing cells, thereby restoring a WT-
like PN that would be expected to be optimized for CFTR
biogenesis and proteome function. While abrogation of the MSR
by siHSF1 did not affect CFTR transcription, global protein
synthesis, or other tested PN pathways (UPS, autophagy, and
oxidative stress), it specifically abrogated both the HSR and UPR
activation, restoring function. It also improved folding and activity
of the FLuc reporter sensor. Thus, we now suggest that early
translation-linked events could be critical determinants of HSR,
disease onset and/or progression promoting the MSR, a
conclusion consistent with the increasing regulatory complexity
of the HSR at the level of transcription [96,107,108].
Why does the HSR work acutely but trigger a maladaptive state
when chronically active in misfolding disease, triggering MSR?
One possibility is that during evolution, the HSR pathway evolved
Figure 8. Q-state management of MSR to correct human disease. Illustrated is the activation state of the HSR in response to acute stress (red)
or to the MSR (blue) seen in disease. Acute HSR activation, seen during acute stress insults, protects from and/or corrects misfolding and rapidly
returns to basal levels, allowing normal biology to resume. In misfolding disease, chronic activation of the HSR alters the normal, physiologic Q-state
(Qn) because of the continued expression of misfolded protein. Once chronically elevated (Q*), the folding environment becomes maladaptive as it
fails to return to the Qn (light yellow area). Down-regulation of the MSR by siHSF1, sip23, or triptolide promotes a reduction of the Q*, which now falls
within the proteostasis buffering capacity (green line), promoting a more normal cellular folding environment. This effect can be further improved
(purple line) when combined with protein fold correctors (pharmacologic chaperones; PCs) which impart improved thermodynamic stability to the
fold, or proteostasis regulators (PRs) that improve protein Q-state biology, improving function of disease-related misfolded protein and its
proteome’s associated environment, promoting abrogation of the chronic stress and improving health.
doi:10.1371/journal.pbio.1001998.g008
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strategies to manage long-term proteostasis states that are
necessary for optimizing stemness [21,105,109] and/or direct
long-term development, differentiation and multi-organ genesis,
required for integrated organismal function, and to extend lifespan
[24,110]. Such a finely tuned Q-state in higher eukaryotes may be
less permissive to fluctuations in PN biology in response to
inherited variants in human disease that become out of reach of
the normal proteostasis buffering capacity, and therefore more
prone to maladaptation [5,28,39,111]. Curiously, maladaptation
not only includes the role of the HSF1-Hsp90 axis in supporting
proliferation of cancer cells, a pathogenic state [28,38,39,112], but
also the propagation and resistance of viral pathogens to host
defenses that can impact human health [113–115]. We would now
propose maladaptation as a potent force in evolvability
[21,105,109], contributing to improved survival and fitness
[5,6,18,116], highlighting an important principle applicable to
correction and increased survival in response to chronic human
disease, perhaps through epigenetic mechanisms that, we now
appreciate, play a central role in HSF1 management [107,108]
and correction of human disease [28,33,56]. We now suggest that
an appreciation of the impact of maladaptation on protein folding
dynamics managed by the Q-state [4,5] could provide insight into
how to effectively manage the vast array of chronic protein
misfolding states affecting human disease [1].
Materials and Methods
Cell Lines
Human bronchial epithelial cells CFBE41o- stably expressing
F508del-CFTR or WT-CFTR were cultured as previously
described [56]. IB3 cells expressing WT-AAT or Z-AAT were
cultured as previously described [33]. For all temperature-
corrected experiments, F508del-CFTR expressing CFBE cells
were transferred to 30uC for 24 h. Hela cells stably expressing WT
or I1061T-NPC1 were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS),
2 mM L-glutamine, 3 mg/ml puromycin, and 600 mg/ml G418.
Primary fibroblasts derived from healthy donors (WT) or patients
homozygous for the I1061T mutation of NPC1 were cultured
in DMEM containing 10% (v/v) FBS, and 2 mM L-
glutamine.
Culturing Primary Human Bronchial Epithelia Cells
Cells were obtained from Scott Randall at UNC Chapel Hill.
Cells were plated on PureColl100 coated plates and grown in
bronchial epithelial growth media (BEGM) + bullet kit (Lonza) +
1 mM all-trans retinoic acid with daily media changes until cells
reached 90% confluence. Cells were harvested with Accutase at
37uC for 10 min and pelleted at 500 g for 5 min. Cells were
re-suspended in BEGM and plated on human placental collagen
coated 12 mm Costar snapwell filters (Corning) at a density of
56105 cells/filter. Cells were grown in liquid/liquid culture for the
first 96 h with daily media changes as previously described [117]
on the apical (0.5 ml) and basolateral (2 ml) chambers. Cells were
subsequently switched to air/liquid culture and basolateral media,
changed every day for the first 7 days and three times a week for
4–6 weeks until differentiation was complete.
Culture of Organoids from Human Rectal Biopsies
Culture of organoids was performed as previously described
[77]. Briefly, biopsies were washed with cold, complete chelation
solution and incubated with 10 mM EDTA for 30 (small intestine)
or 60 (rectum) min at 4uC. Crypts were isolated by centrifugation
and embedded in Matrigel (growth factor reduced, phenol free;
BD bioscience) and seeded (50–200 crypts per 50 ml Matrigel per
well) in 24-well plates. The Matrigel was polymerized for 10 min
at 37uC and immersed in complete medium (DMEM/F12 with
penicillin and streptomycin, 10 mM HEPES, Glutamax, N2, B27
[Invitrogen], 1 mM N-acetylcysteine [Sigma]) and the following
growth factors: 50 ng/ml mouse epidermal growth factor (mEGF),
50% Wnt3a-conditioned medium and 10% noggin-conditioned
medium, 20% Rspo1-conditioned medium, 10 mM nicotinamide
(Sigma), 10 nM gastrin (Sigma), 500 nM A83-01 (Tocris), and
10 mM SB202190 (Sigma). Medium was changed every 2–3 days.
Organoids were passaged every 7–10 days, and passages 1–10
were used for confocal live-cell imaging.
Generation of WT-CFTR and F508del-CFTR Stable CFBE
Cell Lines Expressing WT Firefly Luciferase (FLuc)
The gene coding for the eYFP fluorescent protein was fused at
the C-terminus of the WT Firefly luciferase gene (FLuc) and
cloned into the lentivirus vector, pLVX-Puro (Clontech). CFBE
cells stably expressing WT- or F508del-CFTR were infected with
56106 PFU of pLVX-Puro-eYFP-FLuc lentivirus. Cells expressing
eYFP-FLuc fusion protein were sorted by FACS to generate WT-
or F508del-CFTR CFBE cell lines stably expressing eYFP-FLuc.
siRNA Knockdown, Overexpression, and Preparation of
Cell Lysates and Western Blotting
siRNA transfections and preparation of cell lysates and Western
blots was done as previously described [56]. For overexpression
experiments, cells were plated at 70% confluency in a 12-well plate
and transfected using 1 mg of DNA, 2 ml of P3000 per mg of DNA,
and 1.5 ml of lipofectamine 3000 in Opti-MEM containing 5%
FBS (Life Technologies). Cells were washed and fed on the next
day and lysed 48 h after transfection.
qRT-PCR
qRT-PCR was performed using the iScript One-Step RT-PCR
kit with SYBR green (Bio-Rad). RNA was standardized by
quantification of beta-glucuronidase (GUS) mRNA, and all values
were expressed relative to GUS. Statistical analysis was performed
on three independent technical replicates for each RNA sample,
where error bars represent SD or SEM.
Immunoprecipitation
For each immunoprecipitation (IP), 1 mg of total protein was
used. CFTR IP was performed as previously described [118]. For
HSF1 IP, cells were lysed in 20 mM Tris-HCl pH 7.4, 130 mM
NaCl, 10 mM Na2MoO4, 1 mM EDTA, 5 mM ATP, 0.5% NP-
40, and 2 mg/ml of complete protease inhibitor cocktail. Lysates
were incubated with 3 ml of HSF1 antibody (Abcam, ab52757) for
18 h, and complexes were recovered with 30 ml of c-bind beads
incubated at 4uC for 90 min. The beads were washed three times
with lysis buffer and eluted with 10% SDS and 20% Tris-HCl
pH 6.8.
Pulse and Pulse-Chase Analysis
For total protein synthesis, cells were starved in methionine-free
MEM (Sigma) for 30 min and subsequently pulse labeled for 1 h
with 35S-methionine (0.1 mCi per well in a 6-well plate). Lysates
were loaded in a 4%–20% gradient gel, with the amount of lysate
normalized for number of cells in each condition. CFTR or HSF1
processing efficiency was measured by pulse-chase. Analysis of
CFTR stability by pulse-chase was performed as previously
described [56]. For HSF1 pulse-chase, cells were starved in
methionine-free MEM (Sigma) for 30 min, pulse labeled for 4 h
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with 35S-methionine (0.1 mCi per well in a 6-well plate), and
chased for a total of 24 h. Cells were lysed and HSF1 IP
performed as described above. The recovered radiolabeled
proteins were then visualized by autoradiography.
Iodide Efflux Assay
CFBE cells were seeded in 60 mm dishes at a density of 46105
one day prior to transfection. Iodide efflux assay was performed as
previously described [119].
CFBE-YFP Quenching Assay
CFBE41o- cells stably expressing the halide sensitive YFP-
H148Q/I152L [120] (CFBE-YFP), were dosed with compounds
24 h before the YFP-assay, which was performed as previously
described [40].
Transepithelial Short Circuit Current (Isc) Measurements
Primary human bronchial epithelial (hBE) cells were dosed
every 24 h for a total of 96 h with the indicated concentration of
DMSO, VX809, or triptolide. Cells were mounted in modified
Ussing chambers, and the cultures were continuously short-
circuited with an automatic voltage clamp. Transepithelial
resistance, RT, was measured periodically from the current
required to apply a 2.5 mV bipolar voltage pulse. RT was
calculated from Ohm’s law. The basolateral bathing Ringer
solution was composed of (137 mM NaCl, 4 mM KCl, 1.8 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose).
NaCl concentration of the apical bathing solution was reduced by
replacing NaCl with equimolar Na-gluconate. The chambers were
maintained at 37uC and gassed continuously with a mixture of
95% O2, 5% CO2. Sodium currents were blocked by addition of
the sodium channel blocker amiloride (10 mM) to the apical
solution. Subsequently, the cAMP agonist, forskolin (10 mM; both
chambers), the CFTR potentiator genistein (50 mM; apically), and
the CFTR channel blocker CFTRInh-172 (10 mM; apically)
were added sequentially to determine cAMP-stimulated CFTR
currents.
Determining CFTR Channel Activity in Human Rectal
Organoids
Organoids from a 7-day-old culture (20–80 organoids) were
seeded in a 96-well plate (Nunc) in 5 ml Matrigel and 100 ml of
medium [77]. One day after seeding, organoids were incubated
with 100 ml of medium containing 10 mM calcein green (Invitro-
gen) for 60 min. Then 5 mM forskolin was added, and organoids
were directly analyzed by confocal live-cell microscopy (LSM710,
Zeiss,65 objective). Three wells were analyzed per condition, and
up to 60 wells per experiment. Organoids were pre-incubated for
24 h with 3 mM VX809, 25 nM triptolide, or a combination of
both. For CFTR potentiation, 3 mM VX770 was added with
forskolin. Organoid surface area was automatically quantified
using Volocity imaging software (Improvision). The total organoid
surface (XY plane) increase relative to that at T= 0 of stimulus was
calculated and averaged from two individual wells per condition.
Results are shown as mean 6 SD, and p value determined by two-
tailed t-test using DMSO as a control reference.
HSF1 Cross-Linking
HSF1 cross-linking to monitor HSF1 trimerization status was
performed at room temperature with 1 mM final concentration
of disuccinimidyl suberate (DSS) for 30 min with gentle mixing,
and quenched by addition of 50 mM Tris-HCl pH 7.5 for
15 min.
Luciferase Activity Assay
Prior to the luciferase (Luc) assay, cells were lysed and 15 mg of
total protein loaded on 8% SDS-PAGE gel to perform immuno-
blots for Luciferase and actin control to assess Luc expression level.
Immunoblots were quantified to ensure that the same amount of
Luc was analyzed in the activity assay for each sample. 20 mg of
Luc was incubated with Steady-Glo luciferase assay reagent
(Promega) for 5 min, and luminescence was read at 562 nm to
measure Luc activity. All results are presented as specific FLuc
activity, which represents FLuc activity normalized to the amount
of FLuc expressed in each condition.
AAT Secretion
Three hours before measurement of AAT secretion kinetics,
cells were washed with PBS and incubated with 350 ml (12-well
plate) of FBS-free culture medium. After the 3 h incubation, cells
were harvested, and the corresponding media centrifuged at
1500 rpm for 30 min at 4uC to separate cells and medium. After
lysis, AAT immature and mature forms in the lysate or secreted
into the culture media were analyzed by SDS-PAGE or Native gel
for analysis of AAT polymer formation. For native gel electro-
phoresis, 25 mg of protein in the lysate or 30 ml of cell media was
separated on a 3%–20% native gel according to the manufactur-
er’s instructions (Expedeon Inc). Loading of the media was
normalized to protein concentration in the lysate for each sample.
Native gels were transferred and probed for AAT using the anti-
AAT antibody (Immunology Consultants Laboratory).
AD Mice and Mouse Brain Homogenization
AD mice, referred to as the AbPP Tg mice model, express the
hAPP751 cDNA containing the London (V717I) and Swedish
(K670M/N671L) mutations under the regulatory control of the
murine (m)Thy-1 gene (mThy1-hAPP751). Mice were generated
as previously described [121]. For this study, the APP line 41 mice
(C57/BI6) were utilized, as they produce high levels of Ab42 and
develop synaptic damage and memory deficits. Young (approxi-
mately 4 mo old), middle aged (approximately 9 mo old), and old
(approximately 16 mo old), WT and AD mice pairs were
humanely killed, and tissue was frozen for analysis. Posterior half
of mouse hemibrains were homogenized in 500 ml of PDGF buffer
(1 mM HEPES, 5 mM Benzamidine, 2 mM 2-Mercaptoethanol,
3 mM EDTA, 0.5 mMMagnesium Sulfate, 0.05% Sodium Azide,
2 mg/ml Protease Inhibitor cocktail [Roche], and 1 tablet of
PhosSTOP phosphatase Inhibitor cocktail [Roche] per 10 ml of
buffer, pH 8.8), using a tissue homogenizer. Samples were spun at
5,000 g for 5 min at 4uC, and the supernatant centrifuged at
100,000 rpm for 1 h at 4uC to separate the cytosolic and
particulated fractions. Pellets were resuspended in 150 ml of
PDGF buffer and homogenized by sonication (10% for 10 s).
Protein concentration was determined by Bradford, and 20 mg
protein from cytosolic fractions were loaded in SDS-PAGE for
immunoblotting. To detect Ab monomer and multimers, 40 mg
particulate fractions of brain homogenates were loaded in a 4%–
12% bis-tris gel and immunoblots were incubated with 6E10 Ab
specific antibody (Covance).
CFTR Trypsin Proteolysis
CFBE41o- cells expressing WT- or F508del-CFTR at the
indicated treatment were lysed for 30 min at 4uC with lysis buffer
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100,
2 mg/ml Protease Inhibitor cocktail [Roche]), and harvested at
20,000 g for 20 min at 4uC. Total protein concentration of pre-
cleared lysates was determined by Bradford. Proteolysis was
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performed by incubating 80 mg of total protein with increasing
concentration of Trypsin in PBS (0.01–0.25 mg/ml) at 4uC for
15 min. Proteolysis was stopped by adding 1 mM of PMSF and 6x
SDS-PAGE sample buffer. Samples were equally divided and
loaded onto two 12% SDS-PAGE for separation of the proteolytic
fragments and probed with CFTR antibodies for NBD1 (18D1:
epitope 536-545) and NBD2 (M3A7).
NPC1 Endo-H Digestion
Hela cells expressing WT- or I1061T-NPC1 were transfected
for 72 h, lysed in RIPA buffer (10 mM Tris-HCl pH 8.0,
140 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.1%
Na-deoxycholate, 2 mg/ml Protease Inhibitor cocktail [Roche]),
and harvested at 20,000 g for 15 min at 4uC. NPC1 was
immunoprecipitated using 400 mg of total protein and 2 mg of
NPC1 antibody, for 18 h at 4uC. Complexes were recovered with
40 ml of c-bind beads incubated at 4uC for 2 h. The beads were
washed two times with lysis buffer, and one time with PBS, and
eluted with 36 ml of denaturing buffer (NEB) for 10 min at 90uC.
Elutions were divided in two tubes, one without and other with
1 ml of endo-H enzyme, and incubate for 1 h at 37uC. Samples
were run on 4%–20% gradient gel and immunoblotted for
NPC1.
Data Analysis
The data represents densitometric analysis of immunoblots
using an Alpha Innotech Fluorochem SP. The error bars represent
the SEM (n$3) or the SD of the mean. In all panels asterisks
indicate a p-value ,0.05 as determined by a two-tailed t-test using
the control as the reference.
Supporting Information
Figure S1 Silencing of F508del-CFTR reduces cellular
stress. (A) Immunoblot and quantification (B) of CFTR, HSF1,
and HSF1-P following increased concentration of CFTR siRNA.
CFTR immunoblots show the differential migration pattern of
CFTR ER localized band-B (lower band), and the post-ER
glycoform band-C (higher band). Results are shown as percentage
of control (0 nM siCFTR), which is set to 100%. Results are
shown as mean 6 SD, n$2, and * indicates p,0.05 relative to
control. The underlying data used to make (B) in this figure can be
found in the supplementary file Data S1.
(TIF)
Figure S2 Silencing of p23 does not affect HSF1 mRNA
levels and protein stability. (A) qRT-PCR of HSF1 levels in
F508del-CFTR expressing cells treated with the indicated siRNA.
Results represent a ratio of HSF1 to the housekeeping gene GUS
and normalized to control siRNA, which is set to 100% (mean 6
SD, n$3, * indicates p,0.05 relative to control). (B) Pulse chase of
HSF1 in response to sip23 treatment. (C) The data is expressed as
a percent of HSF1 at time 0 (T= 0). (D) Quantification of the
amount of labeled HSF1 during the pulse phase of the pulse-chase
described in (B). The data is normalized to control siRNA, which
is set to 100% (mean 6 SD, n$2, * indicates p,0.05 relative to
control). (E) Immunoblot of the indicated proteins following p23
silencing in WT-CFTR expressing CFBE cells. Histograms
represent quantification of the indicated proteins upon sip23,
relative to levels seen with control siRNA, which is set to a 100%
(mean 6 SEM, n$3, * indicates p,0.05 relative to control). The
underlying data used to make (A) and (C–E) in this figure can be
found in the supplementary file Data S1.
(TIF)
Figure S3 Silencing of p23 increases F508del-CFTR
stability. Pulse chase analysis of F508del-CFTR (A) and WT-
CFTR (C) in response to p23 silencing. CFTR quantification is
shown as percent of time 0 (T= 0). Curves were plotted by
comparing one-phase exponential decay and linear decay models,
and the best fit was chosen. For F508del-CFTR expressing cells
the control siRNA data fit one-phase exponential decay
(R2 = 0.99), whereas the sip23 data was best fit to the linear decay
model (R2 = 0.97). For WT-CFTR expressing cells control and
p23 siRNA data were best fit in one-phase exponential decay.
Histograms show the amount of labeled F508del-CFTR (B) or
WT-CFTR (D) after the pulse period for the respective pulse-chase
experiments shown in (A) and (C) (mean 6 SD, n$2, * indicates
p,0.05 relative to control). (E) Immunoblots of CFTR and p23
levels in response to sip23 treatment in combination with DMSO
or the proteasomal inhibitor, MG132 (10 mM for 5 h) in F508del-
CFTR expressing cells. Histogram shows the quantitative analysis
of F508del-CFTR glycoforms (band-B and band-C) under the
indicated conditions. Results were normalized to a percent of the
maximum signal for the CFTR band B. Results are shown as a
mean 6 SD, n$3, and p-values determined by two-tailed t-test
using the indicated condition as reference point; * or # indicate
p,0.05. (F) Immunoblots of total and ubiquitinated CFTR (poly-
Ub) in lysates (input) and CFTR immunoprecipitates (IP:CFTR)
in response to sip23 treatment of F508del-CFTR expressing cells.
CFTR2/2 cells lacking CFTR were used as negative control for
CFTR IP. Quantification of CFTR ubiquitination in response to
sip23 treatment is shown, as a ratio of ubiquitin to total CFTR and
the control siRNA set to 1 (n=3). The underlying data used to
make (A–F) in this figure can be found in the supplementary file
Data S1.
(TIF)
Figure S4 HSF1 silencing improves the phenotype of
diseases of protein folding. (A) Quantification of CFTR
following HSF1 silencing in F508del-expressing cells. Results are
shown as a percentage of maximal band-B for CFTR glycoforms.
The C/B ratio is shown as a fold change to that seen in the control
condition (set to 1) (mean 6 SEM, n$3, * indicates p,0.05). (B)
Quantification of the indicated proteins in WT-AAT and in the
mutant Z-AAT) expressing IB3 cells. The data is shown as a fold
change relative to WT-AAT, which is set to 1 (mean6 SD, n$3, *
indicates p,0.05). Quantitative analysis of immature (I), mature
(M) and secreted (S) glycoforms in SDS-PAGE (C) or intracellular
and secreted polymers in Native-PAGE (E) of Z-AAT in response
to siHSF1 treatment in IB3 cells. Results are shown as fold change
relative to control siRNA (mean 6 SD, n$3, * indicates p,0.05).
(D) AAT immunoblots of Native gels, showing intracellular/
cytoplasmic (left blot) or secreted (right blot) Z-AAT treated with
control or HSF1 siRNA, showing AAT monomer seen on WT-
AAT (left arrow) or polymeric forms of Z-AAT (n=3). (F)
Quantification of HSF1 and HSF1-P in primary fibroblasts
derived from WT- or I1061T-NPC1 patients. Results are shown
as fold change relative to WT cells, and represent mean 6 SEM,
n$3, * indicates p,0.05. The underlying data used to make (A–
C), (E) and (F) in this figure can be found in the supplementary file
Data S1.
(TIF)
Figure S5 HSF1 silencing is beneficial in a C. elegans
model of AD. (A) Ab42-CFP cDNA construct, which was
expressed in transgenic C. elegans under the control of the unc-54
muscle specific promoter. (B) Representative microscopic image
showing Ab42 amorphous foci. The white arrow in the right panel
indicates Ab42 expression along muscle filaments. Scale bar: I,
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50 mm, II, 10 mm. qRT-PCR of the levels of I-Hsp70 (C12C8.1,
F44E5.4) after HS in (C) or Ab42 worms in (D) treated with RNAi
against YFP (to silence Ab42-CFP) and HSF-1. Results are shown
as fold change relative to pre-HS in (C) or as a percentage of
control, which is set to 100% in (D) (mean 6 SD). Synchronized
Ab42 worms were treated daily starting at L4 with control RNAi
(L4440) or RNAi against YFP (to silence Ab42-CFP), I-Hsp70
(C12.C8.1 and F44E5.4) (E) or HSF-1 and DAF-2 (F). DAF-2 was
used as positive control for increased longevity. Worm mobility
was assessed daily for the indicated number of days. Each
condition represents data for 100 animals. (G) Quantitative
analysis of Ab42-CFP worm paralysis after 7 days in response to
HSF-1 overexpression (mean 6 SEM). The underlying data used
to make (C–G) in this figure can be found in the supplementary file
Data S1.
(TIF)
Figure S6 Silencing of HSF1 and p23 also affect the UPR
activation present on F508del-CFTR expressing cells. (A)
qRT-PCR of I-Hsp70 (HspA1A), I-Hsp40 (DNAJB1), I-Hsp90
(Hsp90a), and the stress-responsive small heat shock protein
HspB1 (Hsp27), as well as CFTR in F508del-expressing cells after
the indicated siRNA treatment. Results represent a ratio of the
level of the indicated mRNA to the housekeeping gene GUS and
are shown as percentage of control siRNA (* represents p,0.05
relative to control siRNA). (B) qRT-PCR of the indicated genes for
the unfolded protein response (UPR), ubiquitin proteasomal
system (UPS), autophagy, and oxidative stress (NRF2 pathway)
PN pathways upon silencing of HSF1 and p23 in F508del-CFTR
expressing CFBE cells. Results are shown as fold change relative to
control (set to 1, black dotted line) (mean 6 SEM, n$3). (C) qRT-
PCR comparison of UPR and NRF2 genes in WT- F508del- and
CFTR2/2 expressing cells. Results are shown as fold change
relative to WT (set to 1). For all qRT-PCR experiments, results
were normalized to housekeeping gene GUS or TBP (TATA box
binding protein), and are shown as mean6 SEM, n$3; * indicates
p,0.05. (D) Quantification of FLuc activity in WT- or F508del-
CFTR expressing cells treated with DMSO, the proteasomal
inhibitor MG132 (10 mM for 5 h), the autophagy inhibitor 3-
Methyladenide (3-MA, 10 mM for 12 h) or HS at 42uC for 1 h.
The data represents normalized FLuc activity (luminescence/
relative FLuc expression) for each condition. Results are shown as
a mean 6 SEM, n$3; * and # indicate p,0.05 relative to WT-
and F508del-CFTR, respectively. The underlying data used to
make (A–D) in this figure can be found in the supplementary file
Data S1.
(TIF)
Figure S7 Alleviation of the MSR by siHSF1 or triptolide
can improve the effect of other CF correctors. (A) qRT-
PCR of I-Hsp70 (HspA1A) and I-Hsp90 (Hsp90a) levels after HS
of F508del-CFTR expressing cells treated with DMSO or
triptolide (12 nM) for 24 h. The data is normalized to the
housekeeping gene GUS and is shown as fold change relative to
control condition (no HS/DMSO) (mean 6 SD, n$2; * indicates
p,0.05 relative to HS+DMSO). (B) Quantification of CFTR
glycoforms (band-B and band-C, left axis) and associated YFP
quenching referent to F508del channel activity (right axis) for the
indicated treatments of F508del-CFTR expressing CFBE or
CFBE-YFP cells. Results are shown as fold change relative to
DMSO (set to 1) (mean 6 SD, n$3; * indicates p,0.05 relative to
DMSO). (C) Histogram showing the quenching rates (sec-1) of
F508del-expressing CFBE-YFP cells from Fig. 6E. Data represent
the mean 6 SD, n$3. Quantitative analysis of YFP-quenching in
F508del-CFTR expressing CFBE-YFP cells treated with control
siRNA or siHSF1, in combination with DMSO or the indicated
CF correctors (D) or with the indicated chaperone siRNAs (E).
Results are shown as fold change in the percentage of YFP
quenching at 30 s relative to control siRNA/DMSO (D) or control
siRNA (E) set to 1 (Hdac7 siRNA was used as positive control).
Results represent mean 6 SD, n$3; * and # indicate p,0.05
relative to control siRNA/DMSO and siHSF1/DMSO respec-
tively in (D), or relative to siRNA control in (E). The underlying
data used to make (A–E) in this figure can be found in the
supplementary file Data S1.
(TIF)
Data S1 Data used to generate all plots referent to
Figures 1B, E–G, I–L; 2A–E; 3A–F; 4B, F, G; 5A, C, D, F;
6A–E; 7A–C; S1B; S2A, C–E; S3A–F; S4A–C, E, F; S5C–G;
S6A–D; S7A–E.
(XLS)
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